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macrophages were more abundant in IA tumors compared to 
SC tumors and expressed lower levels of MHC class II, indic-
ative of a more immunosuppressive phenotype. Using 9464D 
cells stably expressing firefly luciferase, enhanced IA tumor 
growth could be confirmed using bioluminescence. Col-
lectively, these data show that the orthotopic IA localization 
of TH-MYCN cells impacts the NBL tumor microenviron-
ment, resulting in a more stringent NBL model to study novel 
immunotherapeutic approaches for NBL.
Keywords Neuroblastoma · Orthotopic · Mouse model · 
Bioluminescence · Immunotherapy
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Rae1  Retinoic acid early transcript 1
SC  Subcutaneous
SEM  Standard error of the mean
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Abstract In around half of the patients with neuroblas-
toma (NBL), the primary tumor is located in one of the adre-
nal glands. We have previously reported on a transplantable 
TH-MYCN model of subcutaneous (SC) growing NBL in 
C57Bl/6 mice for immunological studies. In this report, we 
describe an orthotopic TH-MYCN transplantable model 
where the tumor cells were injected intra-adrenally (IA) by 
microsurgery. Strikingly, 9464D cells grew out much faster in 
IA tumors compared to the subcutis. Tumors were infiltrated 
by equal numbers of lymphocytes and myeloid cells. Within 
the myeloid cell population, however, tumor-infiltrating 
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Introduction
Neuroblastoma (NBL) is an aggressive malignancy of 
childhood with a dismal prognosis in high-risk patients. 
NBL arises from any of the parasympathetic nervous tis-
sues in the body. In around half of patients, the primary 
tumor is located in one of the adrenal glands [1]. In a recent 
phase III trial, immunotherapy was added to the current 
standard therapy regimen, which consists of chemotherapy, 
surgery, radiation therapy and autologous stem cell trans-
plantation followed by retinoic acid treatment [2]. The 
addition of this immunotherapy regimen to the standard 
treatment resulted in an improved survival of these high-
risk NBL patients. However, since around half of these 
patients eventually did show progressive disease, a clear 
need remains to improve (immuno)therapy regimens for 
the treatment of NBL.
Most tumors are highly infiltrated by cells of the 
immune system exerting either pro- or anti-tumor effects, 
depending on cell type and activation status [3]. In estab-
lished tumors, however, there is a state of chronic inflam-
mation, paradoxically resulting in local immune suppres-
sion [4, 5]. Regulatory immune cell subsets are actively 
attracted to the tumor that interacts with each other and 
create an immunosuppressive microenvironment [6]. For 
example, M2 macrophages infiltrating tumors can actively 
suppress anti-tumor immune responses via the production 
of anti-inflammatory cytokines [7, 8]. In NBL tumors, the 
presence of tumor-associated macrophages was shown 
to be an independent prognostic factor associated with 
an adverse prognosis8. The immunosuppressive environ-
ment also contributes to progressive or recurrent disease 
during or after immunotherapy. Counteracting the tumor-
induced immune suppression therefore is an important step 
in improving cancer immunotherapy [9]. To achieve this, 
there is a need for a more comprehensive understanding of 
the mechanisms involved in the process of tumor-induced 
immune suppression. To get a better understanding of the 
immunosuppressive environment of NBL tumors and to 
find novel ways to counteract the local immune suppres-
sion, relevant preclinical tumor models are needed [10].
Genomic amplification of the proto-oncogene MYCN 
is consistently associated with a poor prognosis and occurs 
in around 20 % of primary NBL tumors [11]. The TH-
MYCN transgenic mouse model of NBL is driven by the 
over expression of MYCN in the developing sympathetic 
nervous system, eventually resulting in paraspinous NBL 
[12]. In our transplantable model, we inject the tumor cells 
into the adrenal gland, which is a different location than 
the tumors arising in the TH-MYCN transgenic, but more 
like in human adrenal NBL [13]. The spontaneous arising 
NBL tumors in the TH-MYCN model are very similar to 
high-risk human NBL with respect to tumor histology and 
genetics [14, 15]. Cell lines were derived from NBL tumors 
that arose in transgenic TH-MYCN mice. Transplanta-
tion of these cell lines in syngeneic mice also resulted in 
NBL tumors with similar histology and genetics compared 
to human NBL [16, 17]. We recently set up and described 
such a transplantable TH-MYCN model by transplanting 
the TH-MYCN-derived NBL cell line 9464D in C57Bl/6 
mice [18]. In these studies, we found that the immunologi-
cal properties of the transplantable TH-MYCN model were 
similar to those of high-risk human NBL, rendering this 
model a powerful tool in the preclinical development of 
novel immunotherapies for NBL [19].
In our previous studies, the TH-MYCN 9464D NBL 
cells were injected subcutaneously (SC), allowing for exter-
nal measurement of tumor growth [18]. In this study, we 
established an orthotopic transplantable TH-MYCN model 
using 9464D NBL cells and a luciferase expressing 9464D 
variant. Interestingly, the orthotopic intra-adrenal (IA) NBL 
tumors grew out much faster compared to SC NBL tumors 
and were more heavily infiltrated by macrophages exhibit-
ing an immunosuppressive M2 phenotype. We conclude 
that this orthotopic transplantable TH-MYCN model repre-
sents a highly relevant model to develop and understand the 
mechanisms of novel immunotherapies for NBL.
Materials and methods
Animals and cell lines
6- to 8-week-old female C57Bl/6J wild-type (WT) mice 
were purchased from Charles River. Animals were held 
under specified pathogen-free conditions in the Central 
Animal Laboratory (Nijmegen, the Netherlands). All exper-
iments were performed according to the guidelines for ani-
mal care of the Nijmegen Animal Experiments Committee. 
The transgenic cell line 9464D was derived from spontane-
ous tumors from TH-MYCN transgenic mice on C57Bl/6 
background and was a kind gift from Dr. Orentas (NIH, 
Bethesda). 9464D cells were cultured in Dulbecco’s modi-
fied Eagle medium (DMEM) containing 10 % fetal calf 
serum (FCS), 1 % non-essential amino acids, 1.0 % amino 
acids (AA) and 0.05 % β-mercaptoethanol (medium). 
9464D-luc cells were generated as described below and 
cultured in medium containing G418 (200 ng/ml).
Generation of 9464D-luciferase (9464D-luc) clone
9464D cells were transfected with a construct contain-
ing a green fluorescent protein (GFP)-Ires-Luciferase 
sequence under the control of a cytomegalovirus (CMV) 
promoter. Stably transfected 9464D cells were selected by 
adding increasing amounts of G418 to the medium to a 
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final concentration of 200 ng/ml. GFP-positive cells were 
FACsorted and plated as single cells in 96-well plates. 
GFP-positive clones were expanded and selected for sta-
ble transfection by monitoring GFP-positivity by FACS. 
Luciferase expression was determined using a luciferase 
reporter assay; 1 × 105 cells were lysed in 100 μl Pas-
sive Lysis Buffer (Promega), and the lysates were ana-
lyzed for luminescence with the use of the Dual-luciferase 
Reporter Assay System (Promega, Leiden, the Nether-
lands) according to manufacturer’s protocol and a Victor 3 
luminometer (PerkinElmer, Groningen, the Netherlands). 
Several stably transfected clones were expanded, tested 
for cell surface marker expression and frozen for later use.
Subcutaneous and intra-adrenal injection of 9464D 
and 9464D-luc cells
To compare subcutaneous and intra-adrenal tumor growth, 
1 × 106 9464D or 9464D-luc cells from the same batch 
were injected either subcutaneously or intra-adrenally. 
Viability of tumor cells before injection was determined 
by tryptan blue staining and always exceeded 95 %. For 
intra-adrenal injections, microsurgery was performed by a 
skilled biotechnician. Institutional protocols and guidelines 
were adhered to for the delivery of anesthesia and analge-
sia. Briefly, a dorsal incision was made right lateral to the 
spinal cord, and the retroperitoneum was accessed. The 
kidney and adrenal gland were located, and using a 0.3-
ml Becton Dickinson (BD) Micro-Fine™ needle, 1 × 106 
9464D or 9464D-luc cells were injected in a volume of 
30 μl into the adrenal gland. Using sutures, the retroperito-
neum and skin were closed. Within 7 days, sutures could be 
removed and wounds were fully healed without any signs 
of inflammation.
Monitoring tumor growth by bioluminescence
Tumor growth of 9464D-luc tumors at subcutaneous and 
adrenal sites was monitored in time. To prevent blockage 
of light by the black fur, the mice were shaved before each 
measurement. Mice were injected intraperitoneally with 
150 μg D-Luciferin (PerkinElmer, Massachusetts, USA) in 
200 μl phosphate buffered saline (PBS) and anaesthetized 
using isoflurane. Ten minutes after injection of D-Lucif-
erin, mice were imaged using an in vivo imaging system 
(IVIS) Lumina (Xenogen, Almeda, CA, USA) camera by 
taking consecutive 10-s to 2-min imaging frames.
Generation of single cell suspensions of tumors
Tumors were excised on indicated time points and 
mechanically dissociated using large needles followed by 
enzymatic digestion with 1 mg/ml collagenase type III 
(Worthington) and 30 μg/ml DNase type I (Roche) for 1 h 
at 37 °C. After 1 h, ethylenediaminetetraacetic acid (EDTA) 
was added (1.5 mM final concentration) and single cell sus-
pensions were made by passing the tumor fragments over 
100-μm cell strainers.
Antibodies and flow cytometry
For flow cytometric analysis, the directly labeled mAbs 
used were CD11b-PerCP (M1/70), CD4-APC-Cy7 (L3T4) 
and Ly-6G-PE-Cy7 (1A8) from Biolegend, CD45.2-
FITC (104), CD11c-APC (HL3), NK1.1-PE (PK136), 
Ly-6C-APC-Cy7 (AL-21) and CD3-PE (145-2C11) from 
BD, MHC II-PE (M5/114.15.2) from eBioscience. Cells 
for staining were washed in PBS and incubated with Fix-
able Viability Dye eFluor 780 (eBioscience). Cells were 
resuspended in ice-cold PBA and transferred to a V-bottom 
96-wells plate. After incubation for 30 min with PBA con-
taining anti-CD16/CD32 Fc-block (BD), cells were stained 
using specific monoclonal antibodies or the appropriate 
isotype controls for a period of 30 min. Cells were washed 
in PBA and measured on a Cyan apparatus (BD) and ana-
lyzed using Summit software.
Statistics
Data were analyzed using GraphPad 5.0 software. Data are 
presented as means ± standard error of the mean (SEM). 
An unpaired T test (confidence intervals 95 %) was used 
to determine significant differences between two groups. 
Correlation between tumor weight and bioluminescent sig-
nal was determined using a Pearson correlation test (confi-
dence intervals 95 %).
Results
9464D tumors grow out faster in the adrenal gland 
compared to the subcutis
We determined tumor growth of 9464D NBL cells at SC 
and IA sites. A significant difference in tumor weight 
between SC and IA tumors was readily observed at day 
20 post-inoculation (Fig. 1a). Isolation of tumors at day 
35 revealed that IA tumors were again significantly larger 
compared to SC tumors (Fig. 1a). IA tumors grew out 
aggressively, thereby completely destructing the adre-
nal gland, as was evident at necropsy (Fig. 1b). Simi-
lar to human NBL and to previous reports of TH-MYCN 
transgenic tumor models [17, 20, 21], the 9464D tumors 
were hypervascular already on macroscopic examination 
(Fig. 1b). These data show that 9464D tumors grow out 
faster in the adrenal gland compared to the subcutis.
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Adrenal tumors are infiltrated by myeloid cells having a 
more immunosuppressive phenotype
Next, we compared immune infiltration of IA tumors har-
vested on day 20 with SC tumors harvested on day 35. 
Tumors harvested at these time points showed comparable 
tumor weight averages of 624.8 (±357.8 SEM) and 557.0 
(±143.8 SEM) mg (p = 0.86), respectively. Tumors grow-
ing at both anatomical sites were equally infiltrated by 
CD45.2+ tumor-infiltrating leukocytes (TIL); the percent-
age of CD45.2+ TIL of the total tumor cell suspension 
was around 20 % for both anatomical locations (Fig. 2a). 
The amounts of CD11b+ myeloid cells, CD3+CD4+ 
and CD3+CD8+ T cells as well as CD3-NK1.1+ natural 
killer (NK) cells within the CD45.2+ TIL were also simi-
lar for SC and IA tumors (Fig. 2b). Similar to our previous 
observations [18], the largest population of tumor-infil-
trating leukocytes at both tumor locations was CD11b+ 
myeloid cells, making up around 80 % of all CD45.2+ 
TIL (Fig. 2b). Using mAb directed toward the cell sur-
face markers CD11c, Ly-6C, Ly-6G and MHC class II, 
we were able to identify some of the major myeloid cell 
subsets (Fig. 2c). We observed several alterations in the 
distribution of these myeloid cell populations (Fig. 2d). 
In IA tumors, CD11cintLy-6C−Ly-6G−MHCIIint cells hav-
ing a phenotype consistent with macrophages were sig-
nificantly increased compared to SC tumors (Fig. 2d). The 
percentages of CD11chighLy-6C−Ly-6G−MHCIIhigh den-
dritic cells (DC) were decreased in IA tumors compared 
to SC tumors. Also, CD11c−Ly-6ChighLy-6G−MHCIIlow 
cells having a phenotype consistent with monocytic mye-
loid-derived suppressor cells (M-MDSC) were decreased 
in IA tumors compared to SC tumors. In contrast, the 
CD11c−Ly-6CdimLy-6GhighMHCIIlow cells having a phe-
notype consistent with granulocytic myeloid-derived 
suppressor cells (G-MDSC) were increased in IA tumors 
compared to SC tumors (Fig. 2d). To further determine 
the phenotype of these tumor-infiltrating macrophages in 
SC and IA tumors, the surface expression of MHCII on 
these cells was determined (Fig. 2d). The expression lev-
els of MHC class II on DC, M-MDSC and G-MDSC in 
IA and SC tumors, however, were not altered. In contrast, 
tumor-infiltrating macrophages in IA tumors expressed 
significantly lower levels of MHC class II compared to 
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Fig. 1  9464D NBL tumors grow faster in the adrenal gland compared to the subcutis. a Tumor weights of SC and IA 9464D tumors harvested 
on day 20 and day 35 were compared (*p < 0.05; **p < 0.01). b Tumors grow out and destruct the adrenal gland as shown by necropsy
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macrophages infiltrating SC tumors, suggesting a more 
M2 phenotype (Fig. 2e).
Upon analysis of IA NBL tumors harvested at day 
35, these ‘late-stage’ IA tumors were equally infiltrated 
by CD45.2+ TIL, compared to the ‘early-stage’ day 20 
IA tumors (Fig. 3a). Within the CD45.2+ TIL, infil-
tration of CD11b+ myeloid cells, CD3+CD4+ and 
CD3+CD8+ T cells and CD3-NK1.1+ NK cells were 
also similar between ‘late-stage’ and ‘early-stage’ IA 
tumors (Fig. 3b). Upon analysis of the CD45.2+CD11b+ 
myeloid cells, however, the presence of macrophages was 
reduced, while cells having a phenotype of M-MDSC 
were significantly increased in late-stage compared to 
early-stage IA tumors (Fig. 3c). Interestingly, while the 
tumor-infiltrating macrophages expressed similar low 
levels of MHC class II, the more abundant M-MDSC 
now also showed a significant reduction in the expression 
of MHC class II (Fig. 3d).
Fig. 2  Intra-adrenal NBL 
tumors are highly infiltrated by 
macrophages expressing lower 
levels of MHCII. a Leukocyte 
infiltration is similar for SC 
and IA tumors. Percentages of 
CD45.2+ TIL of life-gated total 
tumor cells are depicted for SC 
and IA tumors. b The distribu-
tion of immune cell types within 
the TIL was similar for SC 
and IA tumors. CD45.2+ TIL 
were gated and analyzed for 
the expression of CD11b, CD3, 
CD4, CD8 and NK1.1. Percent-
ages of CD11b+ myeloid cells, 
CD3+CD4+ and CD3+CD8+ 
T cells and CD3-NK1.1+ NK 
cells are depicted for SC and 
IA tumors. c, d The distribu-
tion of myeloid cell subsets 
within total CD11b+ myeloid 
cells is altered between SC and 
IA tumors. CD45.2+CD11b+ 
tumor-infiltrating myeloid cells 
were gated and analyzed for the 
expression of CD11c, Ly-6C, 
Ly-6G and MHCII. Percentages 
of CD11cintLy-6C−Ly-6G− 
macrophages, CD11chighLy-
6C−Ly-6G− dendritic cells, 
CD11c−Ly-6ChighLy-6G− 
M-MDSC and CD11c−Ly-
6CdimLy-6Ghigh G-MDSC are 
depicted for SC and IA tumors. 
(***p < 0.001). e Macrophages 
expressing lower levels of 
MHCII in IA tumors compared 
to SC tumors. MFI’s of MHCII 
on previously gated myeloid 
cell subsets are depicted for SC 
and IA tumors (**p < 0.01)
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Orthotopic 9464D tumors can be monitored 
semiquantitatively using bioluminescence
9464D-luc cells were generated, which were stably biolu-
minescent in luciferase assays and expressed equal levels 
of immune-related cell surface molecules MHC class I, 
retinoic acid early transcript 1 (Rae1), programmed death 
ligand 1 (PD-L1) and the tumor antigen GD2 in vitro com-
pared to the parental 9464D cell line (Suppl. Fig. 1) [18]. 
Following an initial plateau phase, an exponential increase 
in bioluminescent signal was observed for both SC and 
IA 9464D-luc tumors in time (Fig. 4a, b). Similar to the 
parental 9464D tumors, we observed a significant growth 
difference between SC and IA 9464D-luc tumors (Fig. 4c). 
There was a significant correlation between tumor size and 
the corresponding bioluminescent signal, showing that 
semiquantitative measurement of tumor size was feasi-
ble for both SC and IA tumors (Fig. 4d). The correlation 
between NBL tumor weight and the bioluminescent signal 
for IA growing tumors was confirmed in an independent 
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Fig. 3  Late-stage adrenal tumors are highly infiltrated by M-MDSC 
expressing lower levels of MHCII. a Percentage of tumor-infiltrating 
leukocytes (TIL) is similar for day 20 (d20) and day 35 (d35) intra-
adrenal tumors. Percentages of CD45.2+ TIL of life-gated cells are 
depicted for d20 and d35 IA tumors. b The distribution of immune 
cell types within the TIL was similar for d20 and d35 IA tumors. Per-
centages of CD11b+ myeloid cells, CD3+CD4+ and CD3+CD8+ 
T cells and CD3-NK1.1+ NK cells are depicted for d20 and d35 
IA tumors. c The distribution of myeloid cell subset within total 
CD11b+ myeloid cells is altered between d20 and d35 IA tumors. 
CD45.2+CD11b+ tumor-infiltrating myeloid cells were gated and 
analyzed for the expression of CD11c, Ly-6C, Ly-6G and MHCII. 
Percentages of CD11cintLy-6C−Ly-6G− macrophages, CD11chighLy-
6C−Ly-6G− dendritic cells, CD11c−Ly-6ChighLy-6G− M-MDSC and 
CD11c−Ly-6CdimLy-6Ghigh G-MDSC are depicted for d20 and d35 
IA tumors (***p < 0.001). d M-MDSC in late-stage adrenal tumors 
expressing lower levels of MHCII. CD45.2+CD11b+ myeloid cells 
subsets were analyzed for the expression of MHCII. MFI’s of MHCII 
on these cell types is depicted for d20 and d35 IA tumors (*p < 0.05)
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experiment (Fig. 4e). We observed around 15 % CD45.2+ 
TIL in IA 9464D-luc tumors, similar to parental 9464D 
tumors (Suppl. Fig. 2A and Fig. 2A). IA 9464D-luc 
tumors were also highly infiltrated by CD11b+ mye-
loid cells (Suppl. Fig. 2B). Within the tumor-infiltrating 
CD45.2+CD11b+ myeloid fraction, similar myeloid cell 
subset presence and distribution compared to the IA grow-
ing parental 9464D tumors was observed (Suppl. Fig. 2C).
In conclusion, IA 9464D NBL tumors have a distinct, 
more immunosuppressive tumor microenvironment and can 
be monitored using bioluminescence.
Discussion
In this report, we describe an orthotopic model of NBL 
using TH-MYCN transgenic NBL cells. We observed 
that IA 9464D NBL tumors grew faster compared to SC 
tumors. IA NBL tumors were more heavily infiltrated by 
macrophages expressing low levels of MHC class II, sug-
gesting a more immunosuppressive microenvironment. 
Using luciferase-transfected NBL cells, it was feasible to 
monitor tumor growth in the adrenal gland in a semiquanti-
tative manner by measuring the bioluminescence.
In previous studies, orthotopic tumors were shown to 
resemble the tumor biology of human tumors more closely 
than ectopic tumors [22, 23]. The local tumor microenvi-
ronment can influence both tumor cell biology as well 
as tumor cell invasion or metastasis and even therapy 
responses [23–29]. For example, injection of syngeneic 
pancreatic adenocarcinoma cells in the pancreas resulted 
in enhanced tumor growth compared to subcutaneous sites 
and differential expression of the tumor antigen Muc1 [30]. 
Our data also show that orthotopic NBL tumors growing 
in the adrenal gland have a different growth pattern and 
immune infiltration compared to ectopic growing NBL 
tumors. A plausible explanation for the faster 9464D NBL 
growth at orthotopic sites is the induction of a more immu-
nosuppressive environment. We observed marked altera-
tions in myeloid cell subsets and phenotype between SC 
and IA tumors of similar size. The most striking finding 
was that IA tumors were more densely infiltrated with mac-
rophages expressing low levels of MHC class II, suggesting 
a more M2-like macrophage phenotype. Asgharzadeh et al. 
[8] showed that the infiltration of M2-like macrophages in 
disseminated NBL tumors was associated with an adverse 
prognosis. Therefore, our data suggest that the local envi-
ronment in IA NBL tumors is more immune suppressive, 
resulting in more aggressive tumor growth.
These data are in agreement with data from Carlson 
et al. [31], showing that tumor-infiltrating macrophages 
acquire a more M2 phenotype in spontaneous TH-MYCN 
transgenic tumors. Thus, the immune infiltration in our 
orthotopic transplantable TH-MYCN model shows high 
similarity with the immune infiltration observed in NBL 
tumors in the original TH-MYCN transgenic mouse. NBL 
tumors in these TH-MYCN transgenic mice, however, arise 
in a stochastic fashion after a latent period. Tumor growth 
can be controlled more easily using the transplantable TH-
MYCN model presented here. This model therefore allows 
for faster screening of novel therapies for NBL.
In most orthotopic tumor models, as in our ortho-
topic TH-MYCN model, it was not feasible to monitor 
tumor growth via external measurements. For this pur-
pose, we generated a stably transfected clone of 9464D 
cells expressing firefly luciferase. Using this 9464D-luc 
cell line, we were able to monitor growth of SC and IA 
tumors. Tumor size and bioluminescent signals signifi-
cantly correlated, suggesting that semiquantitative moni-
toring of tumor growth was feasible. The observed corre-
lation between tumor size and bioluminescent signal also 
suggests that the NBL tumors are not highly necrotic, as 
extensive tumor necrosis was shown to result in a loss of 
correlation between tumor size and bioluminescent signal 
[32]. The black fur of C57Bl/6 mice can significantly block 
the light coming from the tumor. Shaving of the skin at the 
imaged areas was therefore performed to prevent loss of 
signal. In SC tumors, the bioluminescent signal was higher 
compared to IA tumors, most likely as a result of the more 
superficial location of the subcutaneous tumors. One draw-
back of using bioluminescence in an immunological model 
is the introduction of potential novel tumor antigens. The 
9464D-luc cells not only expressed firefly luciferase, but 
also GFP as a reporter protein. Both luciferase and GFP are 
foreign proteins in the mouse and can be recognized by the 
host immune system. This potentially increases the immu-
nogenicity of the tumor cells resulting in a more immu-
nogenic tumor model. Therefore, effective novel immune 
therapeutics in the 9646-luc model are preferentially also 
tested in the parental 9464D model and/or the spontaneous 
TH-MYCN transgenic mouse model.
In summary, IA 9464D NBL tumors grow faster and are 
infiltrated by myeloid cells having a more immunosuppres-
sive phenotype compared to SC NBL tumors. The feasibil-
ity of using bioluminescence allows for careful monitoring 
of the effect of novel therapies on tumor growth. We con-
clude that this orthotopic transplantable TH-MYCN model 
is a relevant model to study multiple aspects of the immu-
nobiology of NBL and to develop novel (immuno)thera-
peutics for NBL.
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